Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 1,908	$ 3,757
Loan receivable from Emergence Global Enterprises Inc. - related party	17,901
Total current assets	19,809	3,757
Property, plant and improvements
Property and equipment, net		148,125
Other assets
Operating lease right-of-use assets		229,284
Other receivable	113,999	424,110
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	1,179,328	1,065,328
Intangible assets, net	4,956,147	5,380,959
Total assets	6,314,142	7,296,422
Current liabilities
Accounts payable	190,716	181,266
Accounts payable – related parties	8,347
Loans payable	527,379	10,121,411
Loans payable – related parties	1,363,354	1,362,600
Convertible notes payable	6,652,448	5,185,412
Convertible notes payable- related parties	2,558,681	2,538,681
Accrued interest	1,125,034	9,585,055
Accrued interest – related parties	1,615,880	1,274,899
Lease liabilities	22,895	44,361
Accrued expenses	641,023	574,723
Total current liabilities	14,705,757	30,868,408
Operating lease liabilities, less current portion	142,102	184,263
Patent acquisition liability	1,380,000	720,000
Convertible notes, less current portion	78,000	1,038,913
Convertible notes - related parties, less current portion		20,000
Total liabilities	16,305,859	32,831,584
Commitments and contingencies (Notes 4, 7, 10, 11, 15, 16, 17, 19, and 21)
Shareholders’ deficit
Common stock; unlimited authorized shares; 27,557,363 and 26,953,363 issued and outstanding as of December 31, 2020 and 2019, respectively. No par value.
Additional paid-in capital	17,068,810	15,775,010
Accumulated deficit	(27,060,527)	(41,310,172)
Total shareholders’ deficit	(9,991,717)	(25,535,162)
Total liabilities and shareholders’ deficit	$ 6,314,142	$ 7,296,422